MX342898B - Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol. - Google Patents

Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.

Info

Publication number
MX342898B
MX342898B MX2012013014A MX2012013014A MX342898B MX 342898 B MX342898 B MX 342898B MX 2012013014 A MX2012013014 A MX 2012013014A MX 2012013014 A MX2012013014 A MX 2012013014A MX 342898 B MX342898 B MX 342898B
Authority
MX
Mexico
Prior art keywords
therapeutic regimens
ethyl
tetrahydronaphthalen
ethylamino
methoxyphenyl
Prior art date
Application number
MX2012013014A
Other languages
English (en)
Other versions
MX2012013014A (es
Inventor
O'dea Louis
Richard Lyttle C
Guerriero Jonathan
Original Assignee
Radius Health Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Health Inc * filed Critical Radius Health Inc *
Publication of MX2012013014A publication Critical patent/MX2012013014A/es
Publication of MX342898B publication Critical patent/MX342898B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a regímenes terapéuticos clínicamente útiles que consisten en la administración de (R)-6-(2-(etil (4-(2-(etilamino) etil) bencil) amino)-4-metoxifenil) -5, 6 ,7 ,8-tetrahidronaftaleno-2-ol.
MX2012013014A 2010-05-12 2011-05-12 Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol. MX342898B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33409510P 2010-05-12 2010-05-12
PCT/US2011/036311 WO2011143469A1 (en) 2010-05-12 2011-05-12 Therapeutic regimens

Publications (2)

Publication Number Publication Date
MX2012013014A MX2012013014A (es) 2013-02-27
MX342898B true MX342898B (es) 2016-10-18

Family

ID=44914714

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013014A MX342898B (es) 2010-05-12 2011-05-12 Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.

Country Status (17)

Country Link
US (2) US20130053448A1 (es)
EP (2) EP3106159A1 (es)
CA (1) CA2799183A1 (es)
CY (1) CY1117893T1 (es)
DK (1) DK2568806T3 (es)
ES (1) ES2585884T3 (es)
HR (1) HRP20160929T1 (es)
HU (1) HUE030072T2 (es)
LT (1) LT2568806T (es)
ME (1) ME02474B (es)
MX (1) MX342898B (es)
PL (1) PL2568806T3 (es)
PT (1) PT2568806T (es)
RS (1) RS54993B1 (es)
SI (1) SI2568806T1 (es)
SM (1) SMT201600263B (es)
WO (1) WO2011143469A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
EP4035664A3 (en) 2014-03-28 2022-11-30 Duke University Treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
RU2769527C2 (ru) 2016-06-22 2022-04-01 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
DK3565542T3 (da) 2017-01-05 2024-07-01 Radius Pharmaceuticals Inc Polymorphic forms of rad1901-2hcl
KR102792490B1 (ko) 2018-07-04 2025-04-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
MX2021009569A (es) 2019-02-12 2021-09-08 Radius Pharmaceuticals Inc Procesos y compuestos.
AU2024286251A1 (en) * 2023-06-05 2026-01-22 Berlin-Chemie Ag Solid elacestrant dihydrochloride compositions, methods of making the same, and methods of treatment using the same

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1547758A (en) 1975-07-29 1979-06-27 Shell Int Research Herbicidal composition
JPH01261381A (ja) 1988-04-12 1989-10-18 Nippon Soda Co Ltd オキサ（チア）ジアゾール誘導体、その製造方法及び殺ダニ剤
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
UA51652C2 (uk) 1995-06-08 2002-12-16 Новартіс Аг Спосіб гідрування імінів
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
BR9710988A (pt) 1996-06-27 2002-01-15 Ligand Pharm Inc Método e compostos moduladores receptores de androgênio
US20090264534A1 (en) 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
FR2770842B1 (fr) 1997-11-13 1999-12-17 Oreal Nouveaux composes derives de n-aryl 2-hydroxy alkylamides
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
JP4154017B2 (ja) 1997-12-30 2008-09-24 久光製薬株式会社 イオントフォレーシス装置および薬物ユニット
US6159959A (en) 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
AU1280701A (en) 1999-11-17 2001-05-30 Novartis Ag Iontophoretic transdermal delivery of peptides
US6544553B1 (en) * 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
EP1246814B1 (en) 1999-12-30 2005-02-16 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
SK9592002A3 (en) 2000-01-28 2003-12-02 Endorech Inc A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit
IL152719A0 (en) 2000-06-28 2003-06-24 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification
CA2418135C (en) 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
CA2420279C (en) 2000-08-24 2011-07-19 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
BR0114909A (pt) 2000-10-26 2004-02-03 Alza Corp Dispositivos de distribuição de drogas transdérmicas possuindo microprotuberâncias revestidas
WO2003011824A1 (en) 2001-07-31 2003-02-13 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
JP2005502654A (ja) 2001-08-13 2005-01-27 メルク　エンド　カムパニー　インコーポレーテッド 選択的エストロゲン受容体調節剤
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
JP2005524630A (ja) 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
US6933321B2 (en) 2002-02-15 2005-08-23 Endorecherche, Inc. Antiandrogenic biphenyls
US7772433B2 (en) 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
JP4554219B2 (ja) 2002-04-24 2010-09-29 メルク・シャープ・エンド・ドーム・コーポレイション エストロゲン受容体調節剤
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
TW200307553A (en) 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
US7799757B2 (en) 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
JP4449746B2 (ja) 2002-07-12 2010-04-14 アステラス製薬株式会社 Ｎ−フェニル−（２ｒ，５ｓ）ジメチルピペラジン誘導体
MXPA05001631A (es) 2002-08-12 2005-08-19 Takeda Pharmaceutical Derivado de benceno fusionado y su uso.
US7383084B2 (en) 2002-10-31 2008-06-03 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
US7662404B2 (en) 2002-10-31 2010-02-16 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized peptides and polypeptides
IL152574A (en) 2002-10-31 2009-09-22 Transpharma Medical Ltd A system for passing through the skin of dry items or dried medicines
US8133505B2 (en) 2002-10-31 2012-03-13 Transpharma Medical Ltd. Transdermal delivery system for dried particulate or lyophilized medications
AU2003286757B2 (en) 2002-11-01 2009-06-04 Merck Sharp & Dohme Corp. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
UA79504C2 (en) 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
WO2004058682A1 (ja) 2002-12-26 2004-07-15 Eisai Co., Ltd. 選択的エストロゲン受容体モジュレーター
US7741352B2 (en) 2003-03-11 2010-06-22 Neurosearch A/S KCNQ channel modulating compounds and their pharmaceutical use
JP2007500245A (ja) 2003-06-10 2007-01-11 スミスクライン ビーチャム コーポレーション 化合物
JP2007505164A (ja) 2003-06-10 2007-03-08 スミスクライン ビーチャム コーポレーション アンドロゲン、グルココルチコイド、ミネラルコルチコイドおよびプロゲステロン受容体のモジュレーターとしての１−アミノナフタレン類
FI20030958A0 (fi) 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
WO2005004842A2 (en) 2003-06-30 2005-01-20 Alza Corporation Formulations for coated microprojections containing non-volatile counterions
EP1643978A1 (en) * 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
JP2007505120A (ja) 2003-09-10 2007-03-08 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体調節因子としての１７−複素環式−４−アザステロイド誘導体。
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
AU2004287414B2 (en) 2003-10-31 2010-11-25 Alza Corporation Self-actuating applicator for microprojection array
WO2005051456A2 (en) 2003-11-13 2005-06-09 Alza Corporation Composition and apparatus for transdermal delivery
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
CA2545048A1 (en) 2003-11-20 2005-06-02 Warner-Lambert Company Llc Androgen receptor modulators
IL159273A0 (en) 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
WO2005060956A1 (en) 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
EP1704161A4 (en) 2004-01-07 2011-06-08 Endorech Inc ON HELIX 12 OBJECTIVE STEROIDAL PHARMACEUTICAL PRODUCTS
ATE476428T1 (de) 2004-01-22 2010-08-15 Lilly Co Eli Selektive modulatoren des östrogenrezeptors zur behandlung von vasomotorischen symptomen
IL160033A0 (en) 2004-01-25 2004-06-20 Transpharma Medical Ltd Transdermal delivery system for polynucleotides
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
WO2005085185A1 (en) 2004-03-03 2005-09-15 Smithkline Beecham Corporation Aniline derivatives as selective androgen receptor modulators
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
GB0405033D0 (en) 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
JP2007223901A (ja) 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途
CN1942187A (zh) 2004-04-08 2007-04-04 默克公司 作为雄激素受体调节剂的17β－乙酰胺－4－氮杂甾体化合物
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
WO2005111028A1 (en) 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
CA2565544A1 (en) 2004-05-11 2005-11-17 Pfizer Products Inc. Benzonitrile derivatives to treat musculoskeletal frailty
AU2005244734A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
RU2006144863A (ru) 2004-05-17 2008-06-27 Акэдиа Фармасьютикалз Инк. (Us) Модуляторы андрогеновых рецепторов и способ лечения заболеваний с их помощью
MXPA06013924A (es) 2004-05-29 2007-07-18 7Tm Pharma As Acidos tiazolaceticos sustituidos como ligandos crth2.
WO2005120483A2 (en) 2004-06-07 2005-12-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
WO2006031715A2 (en) 2004-09-10 2006-03-23 Janssen Pharmaceutica N.V. Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
US7338973B2 (en) 2004-09-20 2008-03-04 Janssen Pharmaceutica N.V. Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
JP4953456B2 (ja) 2004-09-30 2012-06-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）として有用な新規なベンゾイミダゾール誘導体
US8143425B2 (en) 2004-10-12 2012-03-27 Bristol-Myers Squibb Company Heterocyclic aromatic compounds useful as growth hormone secretagogues
WO2006044707A1 (en) 2004-10-13 2006-04-27 Smithkline Beecham Corporation Chemical compounds
CN101052398A (zh) 2004-10-29 2007-10-10 默克公司 作为雄激素受体调节剂的n－(吡啶－3－基)－2－苯基丁酰胺
CN104803916B (zh) 2004-11-16 2017-08-11 詹森药业有限公司 用作选择性雄激素受体调节剂(sarms)的杂环衍生物
JP2008520331A (ja) 2004-11-18 2008-06-19 トランスファーマ メディカル リミテッド 薬剤の経皮的送達のためのマイクロチャネル形成とイオントフォレーシスの組合せ
JP2008520742A (ja) 2004-11-23 2008-06-19 ピーティーシー セラピューティクス， インコーポレイテッド Ｖｅｇｆ産生の阻害に有用なカルバゾール誘導体、カルボリン誘導体およびインドール誘導体
US7585877B2 (en) 2005-01-10 2009-09-08 Acadia Pharmaceuticals, Inc. Aminophenyl derivatives as selective androgen receptor modulators
WO2006113552A2 (en) 2005-04-15 2006-10-26 Smithkline Beecham Corporation Cyanoarylamines
AU2006247738A1 (en) 2005-05-13 2006-11-23 Eli Lilly And Company Substituted N-arylpyrrolidines as selective androgen receptor modulators
JP2008546643A (ja) 2005-06-06 2008-12-25 スミスクライン ビーチャム コーポレーション ４−置換アリールアミン誘導体および医薬組成物におけるその使用
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
WO2007002181A2 (en) 2005-06-24 2007-01-04 Eli Lilly And Company Tetrahydrocarbazole derivatives useful as androgen receptor modulators (sarm)
WO2007005887A2 (en) 2005-07-01 2007-01-11 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds, compositions and uses thereof
US8592452B2 (en) 2005-08-01 2013-11-26 Takeda Pharmaceutical Company Limited Cyclic amine compound
JP2008303145A (ja) 2005-09-22 2008-12-18 Takeda Chem Ind Ltd Ｇｒｋ阻害剤からなる強心薬
US7776859B2 (en) 2005-10-14 2010-08-17 Bristol-Myers Squibb Company Hexahydroimidazopyrazin-3-one compounds useful as modulators of androgen receptor function
WO2007061781A1 (en) 2005-11-18 2007-05-31 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
TW200730505A (en) 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
CA2635251A1 (en) 2005-12-28 2007-07-26 Alza Corporation Stable therapeutic formulations
PL1984343T3 (pl) 2006-01-24 2013-08-30 Janssen Pharmaceutica Nv 2-podstawione benzimidazole jako selektywne modulatory receptora androgenowego (SARM)
RU2435756C2 (ru) 2006-03-03 2011-12-10 Орион Корпорейшн Избирательные андрогенные рецепторные модуляторы
AU2007225056A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
US9119945B2 (en) 2006-04-20 2015-09-01 3M Innovative Properties Company Device for applying a microneedle array
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
EA024161B1 (ru) 2006-07-12 2016-08-31 Юниверсити Оф Теннесси Рисерч Фаундейшн Фармацевтические композиции, содержащие замещенные ациланилиды
US8110562B2 (en) 2006-07-19 2012-02-07 University Of Tennessee Research Foundation Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
CA2660570C (en) 2006-08-24 2016-08-09 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
ES2452343T3 (es) 2006-09-29 2014-04-01 Glaxosmithkline Llc Compuestos de indol sustituidos
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
EP2073789B8 (en) 2006-10-03 2023-02-08 Radius Health, Inc. A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof
WO2008044033A1 (en) 2006-10-11 2008-04-17 Astrazeneca Ab Amide derivatives
UA98777C2 (en) 2006-11-20 2012-06-25 Эли Лилли Энд Компани Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
WO2008124000A2 (en) 2007-04-02 2008-10-16 Ligand Pharmaceuticals Incorporated Thiazole derivatives as androgen receptor modulator compounds
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2008128100A1 (en) 2007-04-13 2008-10-23 The Regents Of The University Of California Small-molecule inhibitors of the androgen receptor
CA2686093C (en) 2007-04-16 2018-05-08 Corium International, Inc. Solvent-cast microneedle arrays containing active
EP2176220B1 (en) 2007-08-07 2013-03-27 Takeda Pharmaceutical Company Limited Pyrrolidin-2-one derivatives as androgen receptor modulators
US20090117158A1 (en) 2007-10-23 2009-05-07 Mahmoud Ameri Transdermal sustained release drug delivery
WO2009065600A2 (en) 2007-11-21 2009-05-28 Technische Universität Dresden Means for treating myosin-related diseases
KR20100099742A (ko) 2007-12-21 2010-09-13 아스트라제네카 아베 안드로겐 수용체 관련 병태의 치료에서 사용하기 위한 이환식 유도체
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
AU2009215843B2 (en) 2008-02-22 2011-09-08 Ellipses Pharma Ltd Selective androgen receptor modulators
WO2009133861A1 (ja) 2008-04-28 2009-11-05 武田薬品工業株式会社 環状アミン化合物
WO2009137104A1 (en) 2008-05-09 2009-11-12 Radius Health, Inc. Combination therapy for breastcancer comprising an antiestrogenic agent
CN102026974B (zh) 2008-05-16 2013-08-28 伊莱利利公司 四氢环戊二烯并[b]吲哚雄激素受体调节剂
WO2010022176A1 (en) 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
CA2742659C (en) 2008-11-04 2016-09-27 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone
WO2010074239A1 (ja) 2008-12-26 2010-07-01 久光製薬株式会社 マイクロニードルデバイス
US20100226966A1 (en) 2009-03-03 2010-09-09 Daddona Peter E Method for transdermal controlled release drug delivery
WO2010118287A1 (en) 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
US20110172609A1 (en) 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
IE20100174A1 (en) 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
ES2719595T3 (es) 2010-05-04 2019-07-11 Corium Int Inc Método y dispositivo para la administración transdérmica de la hormona paratiroidea usando una matriz de microproyección
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
US9693950B2 (en) 2010-05-28 2017-07-04 3M Innovative Properties Company Aqueous formulations for coating microneedle arrays
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
WO2012075375A1 (en) 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
CA2833571A1 (en) 2011-04-22 2012-10-26 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
AU2012345768B2 (en) 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same

Also Published As

Publication number Publication date
SMT201600263B (it) 2016-08-31
HRP20160929T1 (hr) 2016-10-07
CA2799183A1 (en) 2011-11-17
WO2011143469A1 (en) 2011-11-17
DK2568806T3 (en) 2016-08-15
CY1117893T1 (el) 2017-05-17
MX2012013014A (es) 2013-02-27
EP2568806A1 (en) 2013-03-20
LT2568806T (lt) 2016-09-26
EP2568806B1 (en) 2016-05-11
ES2585884T3 (es) 2016-10-10
ME02474B (me) 2017-02-20
HUE030072T2 (en) 2017-04-28
PT2568806T (pt) 2016-08-05
EP2568806A4 (en) 2013-09-11
US9555014B2 (en) 2017-01-31
RS54993B1 (sr) 2016-11-30
SI2568806T1 (sl) 2016-09-30
US20130053448A1 (en) 2013-02-28
WO2011143469A8 (en) 2012-01-19
EP3106159A1 (en) 2016-12-21
US20160022608A1 (en) 2016-01-28
PL2568806T3 (pl) 2017-03-31

Similar Documents

Publication Publication Date Title
MX342898B (es) Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
ECSP23034537A (es) Formulaciones farmaceuticas
MX2010004576A (es) Derivados de pirimidina novedosos.
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
EA201170441A1 (ru) Терапевтические противовирусные пептиды
NI201200072A (es) Métodos y composiciones para tratar cáncer
EA201291220A1 (ru) Производные аминопиримидина в качестве модуляторов lrrk2
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
TW200942524A (en) Novel aminomethyl benzene derivatives
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
IN2012DN06720A (es)
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MX2013004190A (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
IN2012DN03182A (es)
IN2015DN01119A (es)
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
MX392150B (es) Moduladores de receptores canabinoides.

Legal Events

Date Code Title Description
FG Grant or registration